Abstract:1194 Objectives The presence of the gastrin-releasing peptide receptor (GRPR) has been documented in many human cancers including prostate cancer (Pca), breast cancer and lung cancer. Bombesin (BBN) peptide, an amphibian homologue of mammalian GRP, has demonstrated the ability to bind with high affinity and specificity to GRPR. Although a variety of BBN peptides and their analogs, including both agonists and antagonists, have been widely investigated as GRPR targeted imaging probes for cancer imaging in animal models and patients, a PET probe with better performance is still highly desired for clinical applications. In this work, we aim to develop a GRPR targeted PET probe with high clinical translation ability. A novel BBN analogs which contains an 8-amino octanoic acid spacer (named as ZY1) was thus designed and conjugated with the metal chelator NODAGA. The resulting NODAGA-ZY1 was radiolabeled with 68Ga and evaluated for PET imaging of PCa. Methods Synthesis of the ZY1 was done using standard Fmoc solid-phase peptide chemistry, and the NODAGA conjugation was performed using standard coupling reaction. The NODAGA-ZY1 was radiolabeled with 68Ga in 0.1N sodium acetate (pH 5.5) at 55 oC within 15 min. For in-vitro characterization, receptor binding assay was performed to measure the binding affinity of the peptide using 125I-Tyr4-BBN as a radioligand. The competitive uptake and blocking studies in PC-3 cells and serum stability were further accomplished. To characterize the tumor targeting properties, in vivo static PET/CT-imaging at multiple time points (0.5, 1, and 2 h) and ex-vivo biodistribution to specific organs collected after sacrifice at 2 h post-injection were performed for 68Ga-NODAGA-ZY1 and a comparison probe 68Ga-NODAGA-RM1 in PC-3 tumor-bearing nude mice (n=4 per group). Blocking study with large excess of BBN peptides was also accomplished. Results 68Ga-labeling gave high yield (>98 %) with high purity (>98 %) determined by HPLC. The binding affinity of NODAGA-ZY1 was measured to be 1.30±0.35 nM. The radiolabeled probe was stable after 2 hour serum incubation and showed specific uptake in PC-3 cells. Static PET/CT-imaging demonstrated that tumor was clearly imaged with high tumor to background contrast at 0.5, 1 and 2 h post-injection of 68Ga-NODAGA-ZY1. Quantification analysis of PET images revealed that tumor uptake of the probe was 4.64±0.40%, 5.30±0.41 and 5.80±0.42 %ID/g at 0.5, 1 and 2 h post-injection of the probe, respectively. In comparison, for contol group injected with 68Ga-NODAGA-RM1, much lower tumor PET signals were observed at all-time points. The tumor to background ratio (T/N) ratios for both probes were significantly higher than those of the blocking groups. Importantly, the T/N was 17.66±2.47 at 2 h time point for 68Ga-NODAGA-ZY1 , which was nearly two times of the control group with the T/N value of 9.42±1.39. Ex-vivo biodistribution performed at 2 h post-injection also verified the relative low accumulation in the liver (4.21±0.42 %ID/g) and kidney (3.41±0.46 %ID/g), which suggested that the clearance routes of 68Ga-NODAGA-ZY1 were through hepatobiliary and renal systems. Furthermore, much lower tumor uptake of 68Ga-NODAGA-ZY1 was obtained (0.77±0.08 %ID/g at 2 h) in the presence of the blocking peptide, indicating the specific targeting properties of this probe. Conclusions A novel GRPR targeted 68Ga-NODAGA-ZY1 has been facile prepared. In vitro assay and in vivo studies highlight that 68Ga-NODAGA-ZY1 exhibits high stability, binding affinity, specificity, and excellent in vivo tumor imaging properties. It represents a highly promising probe for the PET imaging of PCa for clinical applications.

68Ga-Dota-nt-20.3 Neurotensin Receptor 1 PET Imaging As a Surrogate for Neuroendocrine Differentiation of Prostate Cancer.

68Ga-DOTA-NT-20.3 Neurotensin receptor 1 positron emission tomography imaging as a surrogate for neuroendocrine differentiation of prostate cancer

A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer.

A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models

Development A Clinical Translatable 68Ga-Labeled and Grpr-Targeted Probe for Pet Imaging of Prostate Cancer

In Vitro and in Vivo Comparative Study of 68Ga-Labeled DOTA-, NOTA-, and HBEDCC-chelated Radiotracers Targeting Prostate-Specific Membrane Antigen

61Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging

Clinical study of 68Ga labeled homologue of gastrin-releasing peptide for PET/CT imaging of patient with prostate cancer

Preclinical Evaluation of a Fluorine-18 Labeled Probe for the Detection of the Expression of PSMA Level in Cancer

Evaluation of Neurotensin Receptor 1 As Potential Biomarker for Prostate Cancer Theranostic Use

Preparation of 68Ga-Psma-11 with a Synthesis Module for Micro PET-CT Imaging of PSMA Expression During Prostate Cancer Progression.

Preparation And Biological Evaluation Of [Tc-99m]Tc-Cngu As A Psma-Targeted Radiotracer For The Imaging Of Prostate Cancer

A novel PSMA targeted dual-function near-infrared fluorescence and PET probe for the image-guided surgery and detection of prostate cancer

Synthesis and Evaluation of a Novel Urea-Based 68Ga-Complex for Imaging PSMA Binding in Tumor.

Design, Preclinical Evaluation, and First-in-human PET Study of [68Ga]ga-Psfa-01: a PSMA/FAP Heterobivalent Tracer

68Ga-DOTA-DiPSMA PET/CT Imaging: Biodistribution, Dosimetry, and Preliminary Application in Prostate Cancer

Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer

Experimental study of a novel radionuclide molecular probe18F-NT targeting prostate cancer

Preparation and Biological Evaluation of [<sup>99m</sup>Tc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer

Ga-68-DOTA-DiPSMA PET/CT Imaging: Biodistribution, Dosimetry, and Preliminary Application in Prostate Cancer

Evaluation of gastrin-releasing peptide receptor, prostate-specific membrane antigen, and neurotensin receptor 1 as potential biomarkers for accurate prostate cancer stratified diagnosis